PPCB Propanc Biopharma Inc

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The company focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.00    OTCQB
As of 06/24/2022     OTCMarkets

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Australia
Country of incorporation:  
IPO date:  11/12/2012
Outstanding shares:  149,033,487
Average volume:  16,256,034
Market cap:   $312,970
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy